5-Amino-1MQ

Typical use cases

Dosing guidelines

Titration

No formal human titration schedule exists; community protocols sometimes describe starting at a lower oral dose and increasing gradually over weeks while monitoring tolerance, often run in cycles (e.g., several weeks on followed by a break). This is not medical guidance.

Reconstitution

N/A — typically supplied as an oral capsule or powder; some research preparations are provided as a solution. Not a lyophilized peptide requiring reconstitution.

Injection sites

N/A — oral administration in community use; preclinical studies have used oral and subcutaneous routes in animals

Storage & handling

Store as a dry powder/capsules in a cool, dry place away from light; refrigeration is recommended for long-term storage and for any solution form. Keep sealed and away from moisture.

Side effects

• Gastrointestinal upset (nausea, stomach discomfort) Mild · Uncommon
• Headache Mild · Uncommon
• Fatigue or low energy Mild · Uncommon
• Unknown long-term safety profile (no human safety data) Moderate · Common
• Theoretical effects on NAD+/methylation balance with chronic use Moderate · Rare

Research summary

5-Amino-1MQ (5-amino-1-methylquinolinium) is a cell-permeable, selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) to yield 1-methylnicotinamide. By inhibiting NNMT, the compound is reported to lower intracellular 1-methylnicotinamide and to increase available NAD+ and SAM, which in adipocytes is associated with suppressed lipogenesis and reduced lipid accumulation. The foundational evidence comes from Neelakantan et al. (2018, Biochemical Pharmacology), who showed that selective membrane-permeable methylquinolinium NNMT inhibitors administered to diet-induced obese mice reduced body weight, white adipose mass, adipocyte size, and plasma cholesterol without changing food intake or producing overt adverse findings, alongside cell-culture work showing shifts away from fat-storage gene expression. A 2024 study in Diabetes, Obesity and Metabolism reported that 5A1MQ dose-dependently limited body-weight and fat-mass gain in obese mice while preserving lean mass, improved oral glucose tolerance and insulin sensitivity, reduced hyperinsulinemia, and lessened hepatic steatosis, liver triglycerides, and macrophage infiltration. The entire evidence base is preclinical (rodent and in-vitro); no published human clinical-trial or human pharmacokinetic data exist, so oral bioavailability, half-life, tissue distribution, and elimination in people remain unknown. Animal studies have used both oral and subcutaneous dosing, and long-term safety has not been characterized. As an experimental research chemical, it is not an approved drug, and human dosing figures circulating in community contexts are extrapolations not supported by controlled human data.

Key references

• https://pubmed.ncbi.nlm.nih.gov/29155147/
• https://pubmed.ncbi.nlm.nih.gov/39161060/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/
• https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1410479/full
• https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1-methylquinolinium

Related compounds